Skip to main content
. 2019 Nov 21;55(12):754. doi: 10.3390/medicina55120754

Figure 1.

Figure 1

RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways: current tyrosine kinase inhibitors (TKIs) under clinical trials. Abbreviations—ERK: extracellular-signal regulated kinases; MEK: mitogen-activated and extracellular-signal regulated kinase; mTOR: mammalian target of rapamycin; RAF: Rapidly Accelerated Fibrosarcoma protein; RAS: retrovirus-associated DNA sequences protein; PI3K: phosphatidylinositol 3-kinase.